Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851331 | 0.74 | — | — | |
| SCHEMBL1568413 | 0.72 | GPR3 (0.46) | GPR3HTR2A | |
| SCHEMBL3701625 | 0.63 | NOTUM (0.37) | — | |
| SCHEMBL5618043 | 0.63 | CACNB4 (0.39) | GPR3HTR2ACYP2A6KDM4EALDH1A1 | |
| SCHEMBL28875963 | 0.62 | HTR2B (0.38) | HTR2ACYP2A6KDM4EALDH1A1HPGD | |
| SCHEMBL1635439 | 0.62 | HTR2B (0.51) | CYP2A6KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL12429503 | 0.62 | GPR3 (0.38) | GPR3HTR2ACYP2A6KDM4EALDH1A1 | |
| SCHEMBL11800530 | 0.62 | RAB9A (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL18242146 | 0.62 | HTR7 (0.41) | CYP2A6KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL9126229 | 0.60 | DPP4 (0.41) | HTR2ACYP2A6KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006102594-A1 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-28 | — | — | WO | disclosed |